| abstract |
The present invention relates to a method for treating, preventing or ameliorating a chronic neurodegenerative disorder, in particular progressive muscular atrophy (PMA), said method comprising administering to a subject in need of such a treatment, prevention or amelioration a specific inhibitor of a caspase l-dependent cytokine. Also specific inhibitors of a caspase l-dependent cytokine for treating, preventing or ameliorating a neurodegenerative disorder, in particular PMA, are disclosed herein. Furthermore, the present invention provides for the use of (a) specific inhibitor(s) of a caspase l-dependent cytokine in the medical or pharmaceutical intervention of neurodegenerative disorders. In particular said cytokine to be inhibited is selected from the group consisting of interleukin-1 (IL-1 ), interleukin-18 (IL-18), interleukin-33 and interferon γ (IFN-γ; interferon-gamma) and most preferably said inhibitor to be employed in context of this invention is a human interleukin-1 receptor antagonist (IL-1 Ra), like anakinra. |